Table 3 Treatment and toxicity
All patients (n = 282) | Patients without visceral metastasis (n = 220) | Patients with visceral metastasis (n = 62) | |||
|---|---|---|---|---|---|
Curative treatment (n = 151) | BSC (n = 69) | Palliative treatment (n = 30) | BSC (n = 32) | ||
Dysphagia palliative treatment | |||||
naso-gastric tubes | 15 (5.3%) | 7 (4.6%) | 4 (5.8%) * | 3 (10.0%) | 1 (3.1%) ** |
gastrostomy | 11 (3.9%) | 4 (2.6%) | 6 (8.7%) | 0 | 1 (3.1%) |
endoscopic dilation | 44 (15.6%) | 19 (12.6%) | 14 (20.3%) | 5 (16.7%) | 5 (3.1%) |
oesophageal stent | 63 (22.3%) | 3 (2.0%) | 37 (53.6%) | 5 (16.7%) | 18 (3.1%) |
Initial cancer treatment | |||||
Mucosectomy | 6 (2.1%) | 6 (4.0%) | - | - | - |
PDT | 18 (6.4%) | 14 (9.3%) | 3 (4.3%) | 1 (3.3%) | - |
Surgery | 13 (4.6%) | 13 (8.6%) | - | - | - |
Chemoradiotherapy | 119 (42.2%) | 111 (73.5%) | - | - | - |
Radiotherapy | 8 (2.8%) | 7 (4.6%) | - | - | - |
Chemotherapy | 22 (7.8%) | - | 2 (2.9%) | 20 (66.7%) | - |
Severe adverse effects | 48 (17.0%) | 31 (20.5%) | 4 (5.8%) * | 10 (33.3%) | 3 (9.4%) ** |
Dysphagia evolution † | |||||
Regression at 2 months (n = 229) | 139 (60.7%) | 87 (64.0%) | 25 (52.12%) | 16 (55.2%) | 11 (68.7%) |
Recurrence (n = 103) | 60 (58.2%) | 35 (67.3%) | 15 (68.2%) | 7 (36.8%) | 3 (30%) |